Since the establishment and with years of pioneering mRNA research, our vision has always extended beyond therapeutic development. Leveraging on our leading platform, we will make mRNA-based drug discovery more efficient, effective and safer, which is vital to improving more lives. That is why we consider our proprietary mRNA technology platform our greatest innovation assets.
Abogen is one of very few mRNA biotech companies in the world which possess all key cutting-edge technologies in-house to support full cycle development and operation of mRNA-based therapeutics, ranging from target selection, sequence design, plasmid preparation, in vitro synthesis of mRNA, lipid molecule design, formulation, clinical research, GMP production, to the delivery of mRNA therapeutics to the market.
The platform serves as the engine driving our continuous exploration in mRNA research and development. We have developed mRNA vaccine product candidates for COVID-19. With further improvement of our platform capabilities, we will continue to extend our pipeline to prevention and treatment of other infectious disease, tumor immunity, protein replacement therapy, etc. to deliver the greatest possible impact to people through transformative therapies.
mRNA design, synthesis, and modificationSynthetic mRNA molecules are the active drug substances of mRNA therapeutics. These molecules carry genetic information and instruct human cell to synthesize necessary proteins that can help our body either fight infections or prevent diseases. The structure of mRNA molecule can be divided into five components, including the 5'cap, the 5' and 3' untranscriptional region (UTR), the open reading frame for the gene of interst, and the poly(A) tail. Each component is crucial to the stability and quality of the final product.Our unique technology is capable of synthesizing high-purity mRNA with various optimization methodologies to encode functional proteins, so as to increase the translation efficiency and minimize the undesirable activation of the immune system. With the help of AI, computational biology, high-throughput screening, we have continuously improved the design and optimization of mRNA sequences, promoting the progress of more ideas in early discovery.Our mRNA design and synthesis capabilities were validated by the advancement of our COVID-19 mRNA vaccines. It only takes a few weeks from sequence design to preclinical studies allowing us to track the evolving pandemic and adapt next-generation vaccines to new variants efficiently.
Lipid nano particle (LNP) delivery systemEfficient delivery requires that the mRNA be protected against extracellular degradation. We have accumulated extensive expertise on lipid nanoparticles (LNPs) as non-viral vectors for the delivery of mRNA to target cells. Our proprietary LNPs system can effectively protect the mRNA from degradation, deliver the mRNA to the desired tissues and facilitate the membrane transport, thus to achieve the efficient delivery of mRNA into cells. In addition to the novel cationic lipid used in the COVID-19 vaccine, we have built up a library of cationic lipids and will keep developing new compounds with better efficacy and/or lower toxicity. We also explore new formulations for developing pipelines.
Clinical & commercial manufacturingmRNA-LNP is formulated with lipid ethanol solution and mRNA solution at appropriate flow rates and ratios. The encapsulation efficiency and polymer dispersion index (PDI) are the primary indicators for evaluating quality, which require precise control over such parameters as LNP components, particle size, flow rate, and fluid morphology at a high speed without compromising the quality.We are one of the few companies with mass-scale capacity to manufacture lipid nanoparticles in accordance with rigorous standard. Our unique dynamic precision mixing (DPM) technology produces highly uniform, low-toxic, positively charged, and pH neutral lipid nanoparticles, achieves over 90% encapsulation rate, and allows linear amplification and mass-scale production, ensuring scalable, reliable and efficient supply of mRNA vaccines during pandemics.